Results 211 to 220 of about 17,663 (255)

Comparison of non‐vitamin K antagonist oral anticoagulants on bleeding and thrombosis

Journal of Clinical Pharmacy and Therapeutics, 2021
Limited data are available for the comparison between different non-vitamin K antagonist oral anticoagulants (NOACs) on clinical outcomes. We aimed to provide evidence of different NOACs for patients with non-valvular atrial fibrillation (NVAF).Electronic databases were searched from inception through 22 March 2020 to identify eligible studies in which
Zhiyan Liu, Lingyue Ma, Hanxu Zhang, Guangyan Mu, Qiufen Xie, Shuang Zhou, Zining Wang, Zhe Wang, Kun Hu, Yanjun Gong, Jie Jiang, Qian Xiang, Yimin Cui   +12 more
openaire   +2 more sources

Reversal agents for non-vitamin K antagonist oral anticoagulants

Nature Reviews Cardiology, 2018
The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit coagulation factor Xa. Although clinical studies of NOACs were conducted without antidotes, patient outcomes with major bleeding when receiving NOACs were no worse than those in ...
Jerrold H, Levy, James, Douketis, Jeffrey I, Weitz   +2 more
openaire   +2 more sources

Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation

Hematology/Oncology Clinics of North America, 2016
For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF.
Anna, Plitt, Christian T, Ruff, Robert P, Giugliano   +2 more
openaire   +2 more sources

Non-vitamin K antagonist oral anticoagulants and infective endocarditis

Heart, 2018
To the Editor  We read with great interest the Editorial by Erwin and Lung, which stated that in patients treated with oral anticoagulants and concomitant infective endocarditis, it is recommended to switch/bridge with heparin in the first 2 weeks to decrease the bleeding risk if cerebral embolism occurs, particularly in staphylococcal endocarditis.1 ...
Caldeira, Daniel, Ferreira, Joaquim J, Pinto, Fausto J., Costa, João   +3 more
openaire   +3 more sources

Pros and Cons of Vitamin K Antagonists and Non–Vitamin K Antagonist Oral Anticoagulants

Seminars in Thrombosis and Hemostasis, 2015
Anticoagulant treatment can be currently instituted with two different classes of drugs: the vitamin K antagonists (VKAs) and the newer, "novel" or non-vitamin K antagonist oral anticoagulant drugs (NOACs). The NOACs have several practical advantages over VKAs, such as the rapid onset/offset of action, the lower potential for food and drug interactions,
RIVA, NICOLETTA, AGENO, WALTER
openaire   +4 more sources

Non–Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease

Hämostaseologie, 2021
AbstractThe prevention of atherothrombotic events is the primary goal in the treatment of patients with arteriosclerotic disorders. Despite recent improvements in the management of coronary artery disease (CAD) with revascularization techniques and antiplatelet therapy, some patients remain at risk of recurrent cardiovascular events.
Samer, Al Said, Michael, Ellscheid, Eleftherios T, Beltsios, Norbert, Frey   +3 more
openaire   +2 more sources

Misdosing of Non–Vitamin K Antagonist Oral Anticoagulants in Primary Care

Clinical Therapeutics, 2020
Prescription patterns of non-vitamin K antagonist oral anticoagulants (NOACs) are unknown among primary care physicians, where most patients with nonvalvular atrial fibrillation (NVAF) are diagnosed and followed up. The goal of this study was to evaluate overdosing and underdosing of NOACs in patients with NVAF followed up in primary care and determine
Carlos Seiça, Cardoso, João André, Sousa, Pedro, Simões, Beatriz, Silva, Ana, Albuquerque, Ana, Esperança, Ana, Cibrão, Artur, Correia, Joana, Gonçalves, Joana, Mortágua, José Eduardo, Almeida, Leonor, Oliveira, José, Garcia, Mariana, Duarte, Mariana, Loureiro, Marta, Costa E Silva, Marta, Fraga, Paulo, Lopes, Rui, Brandão, Susana, Miguel, Teresa, Queirós, Gustavo, Santo, Fernando, Silva, João, Sargento-Freitas   +23 more
openaire   +2 more sources

Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis

Journal of Thrombosis and Thrombolysis, 2018
Intracardiac thrombus most commonly develops in the left atrial appendage (LAA) and left ventricle (LV) in the setting of atrial fibrillation (AF) and post-myocardial fibrillation (MI), respectively. Current guidelines recommend that patients with post-MI LV or LAA thrombus should be treated with vitamin K antagonist (VKA).
Eiman Ghaffarpasand, Maneli D. Tehrani, Jolanta Marszalek, Gerald Chi   +3 more
openaire   +2 more sources

Safety of non-vitamin K antagonist oral anticoagulants - coronary risks

Expert Opinion on Drug Safety, 2016
Since the approval and commercialization of non-vitamin K antagonist oral anticoagulants (NOACs; apixaban, dabigatran, edoxaban, and rivaroxaban) several studies and meta-analyses have raised safety concerns regarding myocardial infarction (MI) risk among NOAC-treated patients, particularly with dabigatran.
Daniel, Caldeira, Joaquim J, Ferreira, Fausto J, Pinto, João, Costa   +3 more
openaire   +2 more sources

Epistaxis and Dabigatran, a New Non-Vitamin K Antagonist Oral Anticoagulant

Acta Otorrinolaringologica (English Edition), 2014
Dabigatran is a new non-vitamin K antagonist (VKA) anticoagulant with anti-thrombin action, with supposedly fewer haemorrhagic complications. However, there are actually no established agents to reverse its effect, nor specific coagulation time tests for monitoring it.An observational prospective study was developed, noting epidemiological, clinical ...
Francisco Javier, García Callejo, Carmen, Bécares Martínez, Jordi, Calvo González, Paz, Martínez Beneyto, Marta, Marco Sanz, Jaime, Marco Algarra   +5 more
openaire   +2 more sources